Jekyll and hide: The two faces of amyloid β

Communicative and Integrative Biology

Volumn 5, Issue 5, 2012, Pages 405-407

  Proft, Juliane ^a   Weiss, Norbert ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Amyloid beta (A ); Experimental autoimmune encephalomyelitis (EAE); Multiple sclerosis (MS); T helper cells (TH)

Indexed keywords

EID: 84869763909     PISSN: 19420889     EISSN: 19420889     Source Type: Journal    
DOI: 10.4161/cib.22571     Document Type: Article

References (32)

1. Clanet M. Jean-Martin Charcot. 1825 to 1893. Int MS J 2008; 15:59-61; PMID:18782501.
2. Society NMS. What we know about MS. national MS Society 2012.
3. Grant JL, Ghosn EE, Axtell RC, Herges K, Kuipers HF, Woodling NS, et al. Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 2012; 4:145ra05.
4. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006; 354:942-55; PMID:16510748; http:// dx.doi.org/10.1056/NEJMra052130.
5. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-85; PMID:9445407; http://dx.doi.org/10.1056/ NEJM199801293380502.
6. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120:393-9; PMID:9126051; http:// dx.doi.org/10.1093/brain/120.3.393.
7. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49:489-502; PMID:16476660; http://dx.doi.org/10.1016/j.neuron.2006.01.022.
8. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989; 24:173-82; PMID:2808689; http://dx.doi. org/10.1016/0165-5728(89)90115-X.
9. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12:1005-15; PMID:16960575.
10. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86:7611-5; PMID:2529544; http://dx.doi. org/10.1073/pnas.86.19.7611
11. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by betaamyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1992; 89:10016-20; PMID:1438191; http:// dx.doi.org/10.1073/pnas.89.21.10016.
12. Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer's disease. Science 2003; 302:834-8; PMID:14593170; http://dx.doi. org/10.1126/science.1088469.
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-6; PMID:12130773; http://dx.doi.org/10.1126/science. 1072994.
14. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006; 6:404-16; PMID:16639431; http://dx.doi. org/10.1038/nri1843.
15. Proft J, Weiss N. A protective mutation against Alzheimer disease? Commun Integr Biol 2012; 5:301-3; PMID:23060947; http://dx.doi.org/10.4161/ cib.21799.
16. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8:579-621; PMID:2188675; http:// dx.doi.org/10.1146/annurev.iy.08.040190.003051.
17. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16:406-12; PMID:20348925; http:// dx.doi.org/10.1038/nm.2110.
18. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139-45; PMID:17290272; http://dx.doi.org/10.1038/ nm1551.
19. Esler WP, Wolfe MS. A portrait of Alzheimer secretases--new features and familiar faces. Science 2001; 293:1449-54; PMID:11520976; http://dx.doi. org/10.1126/science.1064638.
20. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4:510-8; PMID:15931259; http:// dx.doi.org/10.1038/nrd1752.
21. Biogen Idec and Elan Pharmaceuticals I. Biogen Idec and Elan Pharmaceuticals, Inc., 2012.
22. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33:91-101; PMID:20061941; http://dx.doi.org/10.1097/WNF.0b013e3181cbf825.
23. Corporation NP. 2012.
24. St George-Hyslop PH. Molecular genetics of Alzheimer's disease. Biol Psychiatry 2000; 47:183-99; PMID:10682216; http://dx.doi.org/10.1016/ S0006-3223(99)00301-7.
25. St George-Hyslop PH. Genetic factors in the genesis of Alzheimer's disease. Ann N Y Acad Sci 2000; 924:1-7; PMID:11193785; http://dx.doi. org/10.1111/j.1749-6632.2000.tb05552.x.
26. Brindle N, George-Hyslop PS. The genetics of Alzheimer's disease. Methods Mol Med 2000; 32:23-43; PMID:21318509.
27. Cruts M, Theuns J, Van Broeckhoven C. Locusspecific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012; 33:1340-4; PMID:22581678; http://dx.doi.org/10.1002/ humu.22117.
28. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against betaamyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009; 65:24-31; PMID:19194878; http://dx.doi.org/10.1002/ ana.21475.
29. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA, et al. Protective and therapeutic role for alphaBcrystallin in autoimmune demyelination. Nature 2007; 448:474-9; PMID:17568699; http://dx.doi.org/10.1038/nature05935.
30. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloidbeta peptide: a case report. Nat Med 2003; 9:448-52; PMID:12640446; http://dx.doi.org/10.1038/ nm840.
31. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002; 415:462; PMID:11823817; http://dx.doi.org/10.1038/415462a.
32. You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Mol Pain 2011; 7:89; PMID:22093952; http:// dx.doi.org/10.1186/1744-8069-7-89.